Drug Type TCR-T Cell therapy |
Synonyms allogeneic HLA-C*08:02-restricted T-cell receptors targeting mutant KRAS G12D, allogeneic HLA-C*08:02–restricted T-cell receptors targeting mutant KRAS G12D, KRAS G12D TCR细胞疗法 |
Target |
Action inhibitors, stimulants |
Mechanism KRAS G12D inhibitors(GTPase KRas G12D inhibitors), Immunostimulants |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseClinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | Clinical | United States | 02 Jun 2022 |
Pubmed | Br Dent J Manual | Not Applicable | Pancreatic Cancer KRAS G12D | 1 | ayedimbitz(blbkzheobn) = bqtofwluhd rnzqycldvo (qaqomivxws ) | Positive | 02 Jun 2022 |